{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:11Z","timestamp":1790812811841,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["317445"],"award-info":[{"award-number":["317445"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003426","name":"G\u00f6ran Gustafssons Stiftelse f\u00f6r Naturvetenskaplig och Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Immunol"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>Checkpoint blockade of CTLA\u20104 results in long\u2010lasting survival benefits in metastatic cancer patients. However, patients treated with CTLA\u20104 blockade have suffered from immune\u2010related adverse events, most likely due to the breadth of the induced T\u2010cell activation. Here, we investigated the efficacy of a local low\u2010dose anti\u2010CTLA\u20104 administration for treatment of subcutaneous or orthotopic murine bladder 49 (MB49) bladder carcinoma in C57BL\/6 mice. When MB49 tumors were grown s.c., peritumoral (p.t.) injection of anti\u2010CTLA\u20104 treatment was equally effective as intravenous or s.c. (nontumor bearing flank) administration. Notably, p.t. injection was associated with lower circulating antibody levels and decreased IL\u20106 serum levels as compared to systemic treatment. Ultrasound\u2010guided intratumoral anti\u2010CTLA\u20104 antibody treatment of orthotopically growing MB49 tumors resulted in tumor regression, with more than tenfold reduction in systemic antibody levels as compared to i.v. or s.c. administration, in line with the compartmentally restrained nature of the bladder. Local anti\u2010CTLA\u20104 therapy in combination with anti\u2010PD\u20101 therapy resulted in complete responses, superior to each therapy alone. In addition, p.t. anti\u2010CTLA\u20104 therapy was potentiated by depletion of regulatory T cells. Our results demonstrate that local anti\u2010CTLA\u20104 antibody therapy is equally effective as systemic administration, but reduces systemic antibody levels and cytokine release, and enhances the response to anti\u2010PD1 therapy.<\/jats:p>","DOI":"10.1002\/eji.201646583","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T08:52:39Z","timestamp":1479804759000},"page":"385-393","source":"Crossref","is-referenced-by-count":71,"title":["Local checkpoint inhibition of CTLA\u20104 as a monotherapy or in combination with anti\u2010PD1 prevents the growth of murine bladder cancer"],"prefix":"10.1002","volume":"47","author":[{"given":"Luuk","family":"van Hooren","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"Sandin","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Moskalev","sequence":"additional","affiliation":[{"name":"Vancouver Prostate Centre University of British Columbia  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB  Lund Sweden"},{"name":"Department of Immunotechnology Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dimberg","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Black","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"T\u00f6tterman","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Mangsbo","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(05)80055-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27745"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2070"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64859"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594010-000000000-00000"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(80)90384-3"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-19"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27614"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0781"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.04.043"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0569"},{"key":"e_1_2_6_21_1","first-page":"CD005493","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie J. B.","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0067"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002504"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2888"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181587d29"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181c01fcb"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0385"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059536"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.11.009"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00544-6"}],"container-title":["European Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Feji.201646583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/eji.201646583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:55:33Z","timestamp":1695732933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/eji.201646583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1002\/eji.201646583"],"URL":"https:\/\/doi.org\/10.1002\/eji.201646583","archive":["Portico"],"relation":{},"ISSN":["0014-2980","1521-4141"],"issn-type":[{"value":"0014-2980","type":"print"},{"value":"1521-4141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]}}}